Oxandrolone Articles
Savient restructures following generic appro
15 January 2007
Savient files patent suit against Sandoz
11 December 2006
B-TG's Oxandrin OKed In Russia
12 March 1998
US Corporate 1997 Year-End Results Round-Up
11 February 1998
"Highly Pleasing" 1996 Results At BTG
10 March 1997
FDA To Initiate Full Review Of Bio-Technology General's Oxandrin
4 November 1996
BTG's First Profitable Year
15 April 1996
BTG Launches Anabolic Steroid Oxandrin In The USA
4 December 1995
1994 Brings Israel's BTG Closer To Goals
3 July 1995
BTG Achieves First Quarter of Profitability
5 September 1994
hGH IN JAPAN BOOSTS BIOTECH GENERAL SALES
13 June 1994
BIO-TECHNOLOGY GENERAL RECEIVES APPROVAL
31 January 1994
WORLD PRODUCT NEWS IN BRIEF
24 January 1994
BIOTECH GENERAL LOSS DESPITE GOOD SALES GROWTH
22 November 1993
ISRAEL'S GYNEX AND USA'S BTG TO MERGE
21 June 1993
OXANDRIN AND ALCOHOLISM
10 May 1993
CLINICAL STUDY FOR OXANDRIN
5 April 1993
BIOT-TECHNOLOGY GENERAL TO ACQUIRE GYNEX
22 March 1993
GYNEX PRODUCT AIDS TURNER'S PATIENTS
8 June 1992
MORTALITY BENEFIT WITH GYNEX' OXANDRIN
17 February 1992
TREATMENT IND FOR GYNEX' OXANDRIN
6 January 1992
Showing 1-22 of 22 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
